• New First-Line Kidney Cancer Combination Gets FDA Nod

    1 month ago - By MedPageToday

    WASHINGTON - The FDA approved the combination of nivolumab plus cabozantinib on Friday for treating advanced renal cell carcinoma in the first-line setting.
    Support for approval came from CheckMate...
    Read more ...

     

  • FDA approves first-line Opdivo-Cabometyx regimen for advanced renal cell carcinoma

    FDA approves first-line Opdivo-Cabometyx regimen for advanced renal cell carcinoma

    1 month ago - By Healio

    The FDA approved nivolumab in combination with cabozantinib as first-line treatment of patients with advanced renal cell carcinoma, according to a manufacturer-issued press release.
    The approval was based, in part, on data presented at ESMO Virtual Congress 2020 from the phase 3 CheckMate -9ER trial, which included 651 patients with advanced or metastatic renal cell carcinoma.
    Of them, 323 patients received 240 mg nivolumab , an anti-PD-1 antibody, every 2 weeks in combination with 40 mg daily cabozantinib , a multitargeted tyrosine
    Read more ...